Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin and Glasdegib in Older AML Patients
NCT04093505Phase 3Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin, glasdegib in acute myeloid leukemia (AML), sponsored by Heidelberg University Hospital. Started Apr 2021; status: terminated.
02
Drugs
gemtuzumab ozogamicinglasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04093505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093505.